Go Pro
→ Ticker Revealed: Pre-IPO Access to 'Next Elon Musk' Company (From Banyan Hill Publishing) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
BeyondSpring Inc. stock logo
BYSI
BeyondSpring
$0.61
-0.9%		$1.17
$0.57
▼
$2.44
$25.28M0.48270,225 shs50,225 shs
Evaxion A/S - Sponsored ADR stock logo
EVAX
Evaxion A/S
$2.96
-1.3%		$3.12
$2.52
▼
$12.15
$24.69M0.2999,680 shs56,786 shs
Lantern Pharma Inc. stock logo
LTRN
Lantern Pharma
$2.03
$2.97
$1.11
▼
$4.70
$25.94M2.35319,179 shs178,922 shs
Poxel France stock logo
PXXLF
Poxel France
$0.26
$0.26
$0.25
▼
$0.26
$7.53M-0.48N/AN/A
7 Energy Stocks to Buy and Hold Forever Cover
7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
BeyondSpring Inc. stock logo
BYSI
BeyondSpring
-6.75%-12.51%-46.04%-63.50%-63.92%
Evaxion A/S - Sponsored ADR stock logo
EVAX
Evaxion A/S
-0.33%-11.76%+6.38%-20.00%+9.09%
Lantern Pharma Inc. stock logo
LTRN
Lantern Pharma
-1.93%-3.79%-22.81%-45.72%-50.25%
Poxel France stock logo
PXXLF
Poxel France
0.00%0.00%0.00%0.00%+4.00%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
BeyondSpring Inc. stock logo
BYSI
BeyondSpring
$0.61
-0.9%		$1.17
$0.57
▼
$2.44
$25.28M0.48270,225 shs50,225 shs
Evaxion A/S - Sponsored ADR stock logo
EVAX
Evaxion A/S
$2.96
-1.3%		$3.12
$2.52
▼
$12.15
$24.69M0.2999,680 shs56,786 shs
Lantern Pharma Inc. stock logo
LTRN
Lantern Pharma
$2.03
$2.97
$1.11
▼
$4.70
$25.94M2.35319,179 shs178,922 shs
Poxel France stock logo
PXXLF
Poxel France
$0.26
$0.26
$0.25
▼
$0.26
$7.53M-0.48N/AN/A
7 Energy Stocks to Buy and Hold Forever Cover
7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
BeyondSpring Inc. stock logo
BYSI
BeyondSpring
-6.75%-12.51%-46.04%-63.50%-63.92%
Evaxion A/S - Sponsored ADR stock logo
EVAX
Evaxion A/S
-0.33%-11.76%+6.38%-20.00%+9.09%
Lantern Pharma Inc. stock logo
LTRN
Lantern Pharma
-1.93%-3.79%-22.81%-45.72%-50.25%
Poxel France stock logo
PXXLF
Poxel France
0.00%0.00%0.00%0.00%+4.00%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
BeyondSpring Inc. stock logo
BYSI
BeyondSpring
1.00
SellN/AN/A
Evaxion A/S - Sponsored ADR stock logo
EVAX
Evaxion A/S
2.67
Moderate Buy$11.00271.62% Upside
Lantern Pharma Inc. stock logo
LTRN
Lantern Pharma
1.00
SellN/AN/A
Poxel France stock logo
PXXLF
Poxel France
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest PXXLF, BYSI, EVAX, and LTRN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/29/2026
Lantern Pharma Inc. stock logo
LTRN
Lantern Pharma
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E+) ➝ Sell (D-)
7/14/2026
Lantern Pharma Inc. stock logo
LTRN
Lantern Pharma
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (D-) ➝ Sell (E+)
7/9/2026
Evaxion A/S - Sponsored ADR stock logo
EVAX
Evaxion A/S
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E+) ➝ Sell (D-)
7/8/2026
BeyondSpring Inc. stock logo
BYSI
BeyondSpring
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
6/29/2026
Lantern Pharma Inc. stock logo
LTRN
Lantern Pharma
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E+) ➝ Sell (D-)
6/11/2026
Evaxion A/S - Sponsored ADR stock logo
EVAX
Evaxion A/S
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
(Data available from 9/1/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
BeyondSpring Inc. stock logo
BYSI
BeyondSpring
$1.75M14.44$0.10 per share5.86($0.59) per share-1.04
Evaxion A/S - Sponsored ADR stock logo
EVAX
Evaxion A/S
$7.53M3.28N/AN/A$2.04 per share1.45
Lantern Pharma Inc. stock logo
LTRN
Lantern Pharma
N/AN/AN/AN/A$0.58 per shareN/A
Poxel France stock logo
PXXLF
Poxel France
N/AN/AN/AN/AN/AN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
BeyondSpring Inc. stock logo
BYSI
BeyondSpring
-$1.01M-$0.12N/AN/AN/AN/AN/A-28.88%11/12/2026 (Estimated)
Evaxion A/S - Sponsored ADR stock logo
EVAX
Evaxion A/S
-$7.71M-$1.21N/AN/AN/AN/A-61.43%-34.23%11/5/2026 (Estimated)
Lantern Pharma Inc. stock logo
LTRN
Lantern Pharma
-$17.12M-$1.62N/AN/AN/AN/A-368.02%-148.62%11/11/2026 (Estimated)
Poxel France stock logo
PXXLF
Poxel France
N/AN/AN/AN/AN/AN/AN/AN/AN/A

Latest PXXLF, BYSI, EVAX, and LTRN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/14/2026Q2 2026
BeyondSpring Inc. stock logo
BYSI
BeyondSpring
-$0.54-$0.02+$0.52-$0.02$8.77 millionN/A
8/14/2026Q2 2026
Lantern Pharma Inc. stock logo
LTRN
Lantern Pharma
-$0.38-$0.57-$0.19-$0.57N/AN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
BeyondSpring Inc. stock logo
BYSI
BeyondSpring
N/AN/AN/AN/AN/A
Evaxion A/S - Sponsored ADR stock logo
EVAX
Evaxion A/S
N/AN/AN/AN/AN/A
Lantern Pharma Inc. stock logo
LTRN
Lantern Pharma
N/AN/AN/AN/AN/A
Poxel France stock logo
PXXLF
Poxel France
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
BeyondSpring Inc. stock logo
BYSI
BeyondSpring
N/A
0.70
0.70
Evaxion A/S - Sponsored ADR stock logo
EVAX
Evaxion A/S
0.69
5.06
5.06
Lantern Pharma Inc. stock logo
LTRN
Lantern Pharma
N/A
1.96
1.96
Poxel France stock logo
PXXLF
Poxel France
N/AN/AN/A

Institutional Ownership

CompanyInstitutional Ownership
BeyondSpring Inc. stock logo
BYSI
BeyondSpring
40.29%
Evaxion A/S - Sponsored ADR stock logo
EVAX
Evaxion A/S
11.04%
Lantern Pharma Inc. stock logo
LTRN
Lantern Pharma
28.62%
Poxel France stock logo
PXXLF
Poxel France
N/A

Insider Ownership

CompanyInsider Ownership
BeyondSpring Inc. stock logo
BYSI
BeyondSpring
29.31%
Evaxion A/S - Sponsored ADR stock logo
EVAX
Evaxion A/S
41.64%
Lantern Pharma Inc. stock logo
LTRN
Lantern Pharma
8.50%
Poxel France stock logo
PXXLF
Poxel France
N/A
CompanyEmployeesShares OutstandingFree FloatOptionable
BeyondSpring Inc. stock logo
BYSI
BeyondSpring
8041.12 million29.07 millionOptionable
Evaxion A/S - Sponsored ADR stock logo
EVAX
Evaxion A/S
608.34 million4.87 millionNo Data
Lantern Pharma Inc. stock logo
LTRN
Lantern Pharma
2012.78 million11.70 millionOptionable
Poxel France stock logo
PXXLF
Poxel France
1528.95 millionN/ANot Optionable

Recent News About These Companies

Poxel nomme Yves Decadt Directeur Général pour accélérer la valorisation du portefeuille et les partenariats stratégiques
June 10, 2026  |  zonebourse.comZ
Poxel Appoints Yves Decadt as Chief Executive Officer to Accelerate Portfolio Development and Strategic Partnerships
June 10, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/sectors/healthcare/articles/poxel-appoints-yves-decadt-chief-181300387.html
Poxel publie son chiffre d’affaires pour le premier trimestre 2026 et fait le point sur sa situation
May 20, 2026  |  fr.finance.yahoo.comhttps://fr.finance.yahoo.com/actualites/poxel-publie-chiffre-d-affaires-060000750.html
Poxel Reports First Quarter 2026 Revenue and Provides a Business Update
May 20, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260519638053/en/poxel-reports-first-quarter-2026-revenue-and-provides-a-business-update/
Poxel: Postponement of the Publication of the 2025 Annual Financial Statements and the Annual Financial Report
April 30, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260430204733/en/Poxel-Postponement-of-the-Publication-of-the-2025-Annual-Financial-Statements-and-the-Annual-Financial-Report/
Poxel : confirme la mise à disposition de l’emprunt obligataire complémentaire Tranche D PDR dans le cadre du plan de continuation
March 26, 2026  |  zonebourse.comZ
Poxel Confirms the Drawdown Under the Additional Tranche D PDR Bond Issue as Part of the Continuation Plan
March 25, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260325001000/en/poxel-confirms-the-drawdown-under-the-additional-tranche-d-pdr-bond-issue-as-part-of-the-continuation-plan/
Poxel publie son chiffre d’affaires pour l’exercice 2025 et fait le point sur sa situation financière
February 16, 2026  |  fr.finance.yahoo.comhttps://fr.finance.yahoo.com/actualites/poxel-publie-chiffre-d-affaires-180200208.html
Poxel Reports its 2025 Revenue and Provides an Update on its Financial Position
February 16, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260216011686/en/poxel-reports-its-2025-revenue-and-provides-an-update-on-its-financial-position/
Poxel annonce la mise en place d’une ligne de financement en fonds propres avec IRIS dans le cadre de la mise en œuvre du plan de continuation
February 3, 2026  |  fr.finance.yahoo.comhttps://fr.finance.yahoo.com/actualites/poxel-annonce-mise-place-d-074000146.html
Poxel Announces the Implementation of an Equity Line With IRIS Capital as Part of the Execution of the Recovery Plan
February 3, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260202723908/en/Poxel-Announces-the-Implementation-of-an-Equity-Line-With-IRIS-Capital-as-Part-of-the-Execution-of-the-Recovery-Plan/
POXEL SA: Le Tribunal des activités économiques de Lyon valide le plan de continuation et met fin à la procédure de redressement judiciaire
January 30, 2026  |  fr.finance.yahoo.comhttps://fr.finance.yahoo.com/actualites/poxel-tribunal-activit%C3%A9s-%C3%A9conomiques-lyon-065700873.html
POXEL SA: The Commercial Court of Lyon Approves the Recovery Plan and Brings an End to the Judicial Reorganisation Proceedings
January 30, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260129049461/en/poxel-sa-the-commercial-court-of-lyon-approves-the-recovery-plan-and-brings-an-end-to-the-judicial-reorganisation-proceedings/
Poxel annonce les résultats de son Assemblée Générale Mixte du 11 décembre 2025
December 11, 2025  |  fr.finance.yahoo.comhttps://fr.finance.yahoo.com/actualites/poxel-annonce-r%C3%A9sultats-assembl%C3%A9e-g%C3%A9n%C3%A9rale-184200463.html
Poxel Announces Results of its Combined General Meeting Held on December 11, 2025
December 11, 2025  |  finance.yahoo.comhttps://finance.yahoo.com/news/poxel-announces-results-combined-general-184200947.html
POXEL SA : Mise à disposition d’un troisième document en réponse aux questions reçues de la part des actionnaires
December 10, 2025  |  fr.finance.yahoo.comhttps://fr.finance.yahoo.com/actualites/poxel-mise-%C3%A0-disposition-d-225900648.html
Poxel publie ses résultats financiers pour le premier semestre 2025
December 10, 2025  |  fr.finance.yahoo.comhttps://fr.finance.yahoo.com/actualites/poxel-publie-r%C3%A9sultats-financiers-premier-075200855.html
Poxel Publishes Its Financial Results for the First Half of 2025
December 10, 2025  |  businesswire.comhttps://www.businesswire.com/news/home/20251209729909/en/poxel-publishes-its-financial-results-for-the-first-half-of-2025/
Biotech : en redressement judiciaire, Poxel esquisse sa stratégie de rebond
November 26, 2025  |  latribune.frL
POXEL SA : Point sur le projet de plan de redressement et organisation d’un webinaire
November 24, 2025  |  fr.finance.yahoo.comhttps://fr.finance.yahoo.com/actualites/poxel-point-projet-plan-redressement-063000574.html

New MarketBeat Followers Over Time

Media Sentiment Over Time

BeyondSpring stock logo

BeyondSpring NASDAQ:BYSI

$0.61 -0.01 (-0.93%)
As of 02:47 PM Eastern

BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company's lead asset is the Plinabulin, a selective immunomodulating microtubule-binding agent that has completed Phase III clinical trials for treatment of non-small cell lung cancer (NSCLC); and as an anti-cancer agent, as well as for the prevention of chemotherapy-induced neutropenia. It is also developing Plinabulin in combination with docetaxel vs. docetaxel alone for the treatment of NSCLC and epidermal growth factor receptor wild type. In addition, the company develops Plinabulin in combination with various immuno-oncology agents and chemotherapy or radiation, including; nivolumab, a PD-1 antibody that is has completed phase 1 clinical trials for the treatment of non-small cell lung cancer; ipilimumab, a CTLA-4 antibody for the treatment of extensive-stage small cell lung cancer; in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers; and pembrolizumab, etoposide, and platinum to treat extensive-stage small cell lung cancer. Further, it engages in the development of three small molecule immune agents in preclinical stages; and a drug discovery platform to develop therapeutic agents from internal research and development efforts and from collaboration. The company was founded in 2010 and is headquartered in Florham Park, New Jersey.

Evaxion A/S stock logo

Evaxion A/S NASDAQ:EVAX

$2.96 -0.04 (-1.33%)
As of 03:26 PM Eastern

Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of metastatic melanoma; EVX-02, a DNA-based vaccine that is in Phase 1/2a trial designed to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, DNA-based cancer vaccine for the treatment of various cancers. Its programs also include some vaccines that are in pre-clinical stage, which includes EVX-B1 for the prevention of S. aureus-induced skin and soft tissue infections in patients undergoing elective abdominal hernia surgery; EVX-B2 to target diseases caused by N. gonorrhoeae; EVX-B3 for eliciting strong humoral antibody and cellular immune response to the bacterial pathogen; and EVX-V1, viral vaccine product candidate for targeting Cytomegalovirus. Evaxion Biotech A/S was incorporated in 2008 and is based in Horsholm, Denmark.

Lantern Pharma stock logo

Lantern Pharma NASDAQ:LTRN

$2.03 0.00 (0.00%)
As of 03:31 PM Eastern

Lantern Pharma Inc., a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. Its product pipeline comprises LP-300, which is in phase 2 clinical trial in combination therapy for never-smokers with non-small cell lung cancer adenocarcinoma; LP-184, which is in phase 1 clinical trial for the treatment of solid tumor, such as pancreatic, breast, bladder, and lung cancers, and glioblastoma and other central nervous system cancers; and LP-284, which is in phase 1 clinical trial for the treatment of non-Hodgkin's lymphomas, including mantle cell lymphoma and double hit lymphoma. The company develops STAR-001, which is in preclinical development for the treatment of glioblastoma, brain metastases, atypical teratoid rhabdoid tumors, and pediatric rare disease designation. In addition, it provides ADC program, an antibody drug conjugate therapeutic approach for cancer treatment. Further, the company's artificial intelligence platform RADR uses big data analytics and machine learning for combining molecular data. Lantern Pharma Inc. has a strategic AI-driven collaboration with Oregon Therapeutics to optimize the development of its first-in-class protein disulfide isomerase inhibitor drug candidate XCE853 in novel and targeted cancer indications. The company was incorporated in 2013 and is headquartered in Dallas, Texas.

Poxel France stock logo

Poxel France OTCMKTS:PXXLF

$0.26 0.00 (0.00%)
As of 08/28/2026

Poxel S.A., a clinical-stage biopharmaceutical company, develops novel treatments for metabolic diseases, type 2 diabetes, and liver diseases. The company's lead product is TWYMEEG (Imeglimin), an oral drug candidate that targets mitochondrial dysfunction and approved for the treatment of type 2 diabetes in Japan. It also develops PXL770, an adenosine monophosphate-activated protein kinase enzyme, which is in a Phase 2a clinical trial that treats chronic metabolic diseases, including diseases that affect the liver, such as non-alcoholic steatohepatitis (NASH); PXL065, an earlier stage programs that is in Phase 2 for the treatment of NASH focusing on chronic and rare metabolic indications. The company has a licensing agreement with Enyo Pharma S.A.S. for the development of farnesoid X receptor that is in Phase 2a study for the treatment of hepatitis B and NASH; and DeuteRx LLC for the development of PXL065, a mitochondrial pyruvate carrier inhibitor, which is in a phase I clinical trial for the treatment of NASH. Poxel S.A. was incorporated in 2009 and is headquartered in Lyon, France.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas